Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations John A. NymanHawre J. Jalal Commentary 11 October 2012 Pages: 173 - 174
Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations Pieter H.M. van BaalAlbert WongG. Ardine de Wit Leading Article 11 October 2012 Pages: 175 - 187
Sample Size and Power for Cost-Effectiveness Analysis (Part 1) Henry A. Glick Practical Application 11 October 2012 Pages: 189 - 198
Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children Chantal W.B. BoonackerPieter H. BroosMaroeska M. Rovers Review Article 11 October 2012 Pages: 199 - 211
Advances in Cancer Therapeutics and Patient Access to New Drugs George DranitsarisIlse TruterWilliam Evans Review Article 11 October 2012 Pages: 213 - 224
Value of Information in the Osteoarthritis Setting Nicholas LatimerJoanne LordPhilip G. Conaghan Original Research Article 11 October 2012 Pages: 225 - 237
Comparing Methods of Data Synthesis Mark OppeMaiwenn AlMaureen van Rutten-Mölken Original Research Article 11 October 2012 Pages: 239 - 250
Posaconazole Katherine A. Lyseng-Williamson Adis Pharmacoeconomic Drug Evaluation 11 October 2012 Pages: 251 - 268